EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

iSpecimen Inc (ISPC) fair value: what the stock is really worth

As of Oct 16, 2026: fair value (intrinsic value) of iSpecimen Inc stock $0.17, price $0.92, upside -81.5%, quality 21 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US45032V3069

II iSpecimen Inc logo Thin data Oct 3, 2026

iSpecimen Inc

ISPC · US

Weakest SetupStrongly overvalued and low quality.

Our calculation puts a fair price 81% below what the stock costs today.

Fair value $0.1700 · Strongly overvalued (−81.5%)
Quality 21/100
Weak Growth (revenue 5y −25.1 %/yr in USD)
Negative free cash flow
Trails peers (1/6)
Narrow moat 12/100
Thin data
⚠ Dilution
Watch iSpecimen Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$16,336 $0.9170 Fair Value $0.1700 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $0.9170 – $16,336 · fair‑value band $0.1105 – $0.2125 · the $0.9170 price screens above the $0.1700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.

Follow iSpecimen in your weekly email

Every Wednesday you see whether iSpecimen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

Show moreShow less

It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.

The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types.

It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

Stock analysis

iSpecimen Inc (ISPC) currently trades at $0.9170, while our model-based Fair Value estimate is $0.1700, 81.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.1105 (bear) to $0.2125 (bull), the price of $0.9170 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

iSpecimen Inc reported revenue of $1.9M in FY2025 versus $11.1M in FY2021, a compound −35.5%/yr. Reported net income was −$10.5M in FY2025.

Key figures

Market cap $2.7M · P/S ratio 5.83 · EPS (TTM) $−46.05 · Return on equity −968% · Return on assets (EBIT) −71.8% · Operating margin −897% · Revenue growth (YoY) −78.7% · Free cash flow −$4.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 97% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −81%, ISPC screens richer than that median.

Fair Value models

Bear $0.1105 Fair Value $0.1700 Bull $0.2125
Price $0.9170 · Upside -81.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.1300 $0.2000 $0.2500 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.1300 $0.2000 $0.2500 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 21/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 35
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 7
How calm the share price moves, does not count
Momentum 0
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−79.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−43.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−25.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−29.4% (2020) → −465.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ISPC screens overvalued: fair value 81% below the price. Compare with Thermo Fisher Scientific Inc →

Compare iSpecimen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 124 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside −81.5% · Bottom 25%
Profitability
Return on assets −110.0% · Bottom 25%
Growth and dividend
Revenue growth −78.7% · Bottom 25%

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 0.88× · Cheaper than median
P/S (12 months) 5.83× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
WuXi AppTec Co 603259 ¥157.85 ¥173.64 +10% vs ISPC
IQVIA Holdings IQV $259.88 $285.87 +10% vs ISPC
Illumina, Inc ILMN $278.17 $295.60 +6% vs ISPC
Thermo Fisher Scientific Inc TMO $663.04 $686.04 +3% vs ISPC
IDEXX Laboratories, Inc IDXX $523.94 $495.84 −5% vs ISPC
Danaher Corporation DHR $224.69 $209.18 −7% vs ISPC
Mettler-Toledo International Inc MTD $1,550 $644.24 −58% vs ISPC
Agilent Technologies, Inc A $171.33 $64.17 −63% vs ISPC
Lonza Group LONN CHF 604.00 CHF 151.89 −75% vs ISPC
Waters Corporation WAT $433.77 $106.46 −75% vs ISPC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

iSpecimen Inc · Fair Value
$0.1700 −81%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "iSpecimen Inc Fair Value". https://www.fairvalue-calculator.com/stock/ISPC

Frequently asked questions

Is iSpecimen Inc (ISPC) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.1700 versus a price of $0.9170, about −81% upside (overvalued).
What is the fair value of ISPC?
Our model-based fair value for iSpecimen Inc is $0.1700 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.9170.
What is the quality score of ISPC?
iSpecimen Inc has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for iSpecimen Inc (ISPC)?
Our model-based price target is the fair value of $0.1700 (as of Oct 3, 2026) from 1 valuation models. Cautious scenario $0.1105, optimistic scenario $0.2125. It is a calculation from audited fundamentals, not an analyst target.
What is the iSpecimen Inc stock forecast for 2026?
Our models put fair value at $0.1700, about −81% upside versus a price of $0.9170 (overvalued). Cautious scenario $0.1105, optimistic scenario $0.2125. The calculation is refreshed regularly with new filings.
What is the intrinsic value of iSpecimen Inc (ISPC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For iSpecimen Inc it is $0.1700 per share (as of Oct 3, 2026), against a price of $0.9170. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is iSpecimen Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, ISPC trades above its calculated fair value: price $0.9170, fair value $0.1700, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ISPC?
No. The price is what the market pays today ($0.9170); the fair value is what the company's own numbers justify ($0.1700). For iSpecimen Inc the two are $0.7470 per share apart. That gap is exactly why we show both numbers side by side.
How much is iSpecimen Inc worth?
The market values iSpecimen Inc at about $2.7M (market capitalisation, as of Oct 3, 2026). Per share that is $0.9170; our models calculate a fair value of $0.1700 per share.
What do the bullish and bearish scenarios say about ISPC?
Our models span a range for iSpecimen Inc: cautious scenario $0.1105, base $0.1700, optimistic $0.2125 per share (as of Oct 3, 2026, price $0.9170). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is ISPC from its 52-week high?
iSpecimen Inc trades at $0.9170, about 97% below its 52-week high of $34.40 and at the low of $0.9170 (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1700 is for.
Which stocks are comparable to iSpecimen Inc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is iSpecimen Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $0.9170, calculated fair value $0.1700 (−81%), Quality Score 21/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ISPC calculated?
We run iSpecimen Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7 % above its aggregate fair value. iSpecimen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of iSpecimen Inc (ISPC)?
The closing price on Oct 16, 2026 was $0.9170. Our model-based fair value is $0.1700, about −81% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with iSpecimen Inc right now?
The price sits above even our optimistic bull case ($0.2125). The favourable scenario is already priced in. Weak quality (21/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.1105 to $0.2125) leaves room in how you read the outcome.

Key figures of iSpecimen Inc

How large is the market capitalisation of iSpecimen Inc (ISPC)?
The market capitalisation of iSpecimen Inc is $2.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of iSpecimen Inc (ISPC)?
The price-to-sales ratio of iSpecimen Inc is 5.83 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of iSpecimen Inc (ISPC)?
Earnings per share at iSpecimen Inc are $−46.05. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of iSpecimen Inc (ISPC)?
The return on equity (ROE) of iSpecimen Inc is −968% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of iSpecimen Inc (ISPC)?
On an EBIT basis the return on assets of iSpecimen Inc is −71.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of iSpecimen Inc (ISPC)?
The operating margin of iSpecimen Inc is −897% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at iSpecimen Inc (ISPC)?
Revenue at iSpecimen Inc is growing −78.7% versus a year earlier (3y avg −43.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does iSpecimen Inc (ISPC) generate?
The free cash flow of iSpecimen Inc is −$4.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does iSpecimen Inc (ISPC) hold?
iSpecimen Inc holds more cash than debt, $6.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch iSpecimen Inc in the live analysis

One click puts iSpecimen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.